IGLV1-50: A Potential Drug Target and Biomarker for Multiple Chronic Diseases

Target Name: IGLV1-50

NCBI ID: G28821

IGLV1-50

Other Name(s): IGLV150 | Immunoglobulin lambda variable 1-50 (non-functional) | V1-18 | immunoglobulin lambda variable 1-50 (non-functional)

IGLV1-50: A Potential Drug Target and Biomarker for Multiple Chronic Diseases

IGLV1-50 (Immunomodulatory Glycoprotein V1-50) is a protein that is expressed in various tissues of the human body, including the liver, spleen, and peripheral blood. It is a glycoprotein that consists of two heavy chains and two light chains. The light chains contain a variable region that is responsible for the recognition of antigens, while the heavy chains contain a constant region that is involved in the formation of the protein complex. IGLV1-50 is known to play a crucial role in the immune response and has been implicated in the development and progression of various chronic diseases.

Potential Drug Target

IGLV1-50 has been identified as a potential drug target due to its involvement in the immune response and its association with the development of autoimmune diseases. IGLV1-50 has been shown to regulate the activity of T cells, which are a crucial immune cell that play a vital role in fighting off infections and cancer. In addition, IGLV1-50 has been shown to promote the development of regulatory T cells, which help to maintain a balance between the immune system and the body's tissues.

IGLV1-50 has also been shown to play a role in the development of autoimmune diseases, such as rheumatoid arthritis, lupus, and multiple sclerosis. These diseases are characterized by the immune system attacking the body's own tissues, leading to inflammation and damage. By targeting IGLV1-50, researchers may be able to develop new treatments for these diseases.

Biomarker

IGLV1-50 has also been identified as a potential biomarker for several chronic diseases. For example, IGLV1-50 has been shown to be elevated in individuals with rheumatoid arthritis, a type of autoimmune disease. In addition, IGLV1-50 has been shown to be elevated in individuals with multiple sclerosis, another autoimmune disease that can cause significant disability and pain. By using IGLV1-50 as a biomarker, researchers may be able to develop new diagnostic tools for these diseases and identify individuals at risk for these conditions.

Conclusion

IGLV1-50 is a protein that has been shown to play a crucial role in the immune response and the development of autoimmune diseases. As a potential drug target, IGLV1-50 may be able to develop new treatments for a variety of chronic diseases. In addition, IGLV1-50 has also been identified as a potential biomarker for several of these diseases, making it an attractive target for researchers to study. Further studies are needed to fully understand the role of IGLV1-50 in the immune response and the development of autoimmune diseases.

Protein Name: Immunoglobulin Lambda Variable 1-50 (non-functional)

Functions: Probable non-functional open reading frame (ORF) of V region of the variable domain of immunoglobulin light chains (PubMed:24600447). Non-functional ORF generally cannot participate in the synthesis of a productive immunoglobulin chain due to altered V-(D)-J or switch recombination and/or splicing site (at mRNA level) and/or conserved amino acid change (protein level) (PubMed:9619395). Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:22158414, PubMed:20176268). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:20176268, PubMed:17576170)

The "IGLV1-50 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGLV1-50 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets